J&J Limited On Offering Consumer Business Separation Details, Clear On Q4 Revenue Drag
Executive Summary
“We made significant progress towards the separation of Kenvue,” says CEO Jaoquin Duoto. But fourth-quarter and full-year progress on consumer sales growth was impeded by loss to foreign currency exchange.
You may also be interested in...
US FDA, Industry Prepare For Potential Spread Of Surging Demand For Children’s Pain Relief OTCs
FDA “understands that manufacturers expect availability to continue to increase in the near future.” CHPA is working with members “focused on safeguarding the US supply by maximizing capacity to produce and direct product to where it is needed most.”
Canada Responds To Children’s OTC Pain Reliever Shortage Linked To Consumers ‘Panic Buying’
Shortage began in August and has increased the onset of cough/cold season due to consumers’ “stockpiling/panic buying” in response to high levels of activity in COVID-19, RSV, seasonal flu and other viruses, according to Canadian Pharmacists Association. Health Canada has approved imports of Haleon and J&J children’s pain relievers.
Checking Boxes Toward Consumer Health Spinoff, J&J Notes Costs For Preparing To Change
Firm adds outside-the-box details about planned spinoff with its third quarter results on 18 October, which included worldwide consumer results slipping 0.4% to $3.8bn on a 2.1% increase in the offset by 2.3% international decline.